Literature DB >> 21088256

β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma.

Sébastien Gaujoux1, Sophie Grabar, Martin Fassnacht, Bruno Ragazzon, Pierre Launay, Rossella Libé, Ilham Chokri, Anne Audebourg, Benedict Royer, Silviu Sbiera, Marie-Cécile Vacher-Lavenu, Bertrand Dousset, Xavier Bertagna, Bruno Allolio, Jérôme Bertherat, Frédérique Tissier.   

Abstract

PURPOSE: Activation of the Wnt/β-catenin signaling pathway is frequent in adrenocortical carcinoma (ACC) and might be associated with a more aggressive phenotype. The objective of this study was to assess the prognostic value of β-catenin immunohistochemistry and CTNNB1 (β-catenin gene)/APC (adenomatous polyposis coli gene) mutations in patients with resected primary ACC. EXPERIMENTAL
DESIGN: In 79 patients with resected primary ACC from a French cohort (Cochin-COMETE), β-catenin expression was assessed on tumor specimens by immunohistochemistry. For patients with available DNA (n = 49), CTNNB1, and APC hotspot (mutation cluster region), were sequenced. Association between these results and the clinicopathologic characteristics of the ACC and overall and disease-free survival were studied. Results were confirmed on a tissue microarray from an independent multicentric cohort of 92 ACC from Germany (German-ENSAT cohort).
RESULTS: In the Cochin-COMETE cohort, the presence of a β-catenin nuclear staining was significantly associated with a higher ENSAT tumor stage (i.e., stages III and IV), higher Weiss score, more frequent necrosis, mitoses, and CTNNB1/APC mutations. β-Catenin nuclear staining and the presence of CTNNB1/APC mutations were both associated with decreased overall and disease-free survival, and were independent predictive factors of survival in multivariate analysis. The same results were observed in the German-ENSAT cohort.
CONCLUSIONS: Wnt/β-catenin activation, confirmed by the presence of β-catenin nuclear staining, is an independent prognostic factor of overall and disease-free survival in patients with resected primary ACC. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21088256     DOI: 10.1158/1078-0432.CCR-10-2006

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  60 in total

Review 1.  Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?

Authors:  E Baudin; S Leboulleux; A Al Ghuzlan; C Chougnet; J Young; D Deandreis; F Dumont; F Dechamps; C Caramella; P Chanson; E Lanoy; I Borget; M Schlumberger
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 2.  Adrenocortical stem and progenitor cells: implications for adrenocortical carcinoma.

Authors:  Derek P Simon; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2012-01-13       Impact factor: 4.102

3.  Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.

Authors:  Kei Satoh; Lisa Zhang; Yaqin Zhang; Raju Chelluri; Myriem Boufraqech; Naris Nilubol; Dhaval Patel; Min Shen; Electron Kebebew
Journal:  Clin Cancer Res       Date:  2016-02-12       Impact factor: 12.531

4.  SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).

Authors:  Thomas G Papathomas; Lindsey Oudijk; Alexandre Persu; Anthony J Gill; Francien van Nederveen; Arthur S Tischler; Frédérique Tissier; Marco Volante; Xavier Matias-Guiu; Marcel Smid; Judith Favier; Elena Rapizzi; Rosella Libe; Maria Currás-Freixes; Selda Aydin; Thanh Huynh; Urs Lichtenauer; Anouk van Berkel; Letizia Canu; Rita Domingues; Roderick J Clifton-Bligh; Magdalena Bialas; Miikka Vikkula; Gustavo Baretton; Mauro Papotti; Gabriella Nesi; Cécile Badoual; Karel Pacak; Graeme Eisenhofer; Henri J Timmers; Felix Beuschlein; Jérôme Bertherat; Massimo Mannelli; Mercedes Robledo; Anne-Paule Gimenez-Roqueplo; Winand Nm Dinjens; Esther Korpershoek; Ronald R de Krijger
Journal:  Mod Pathol       Date:  2015-02-27       Impact factor: 7.842

Review 5.  The cAMP pathway and the control of adrenocortical development and growth.

Authors:  Cyrille de Joussineau; Isabelle Sahut-Barnola; Isaac Levy; Emmanouil Saloustros; Pierre Val; Constantine A Stratakis; Antoine Martinez
Journal:  Mol Cell Endocrinol       Date:  2011-10-15       Impact factor: 4.102

6.  Development and validation of prognostic nomograms in patients with adrenocortical carcinoma: a population-based study.

Authors:  Hao Zhang; Yaser Naji; Minbo Yan; Wenfei Lian; Maochun Xie; Yingbo Dai
Journal:  Int Urol Nephrol       Date:  2020-02-18       Impact factor: 2.370

7.  Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma.

Authors:  Derek P Simon; Thomas J Giordano; Gary D Hammer
Journal:  Clin Cancer Res       Date:  2012-03-16       Impact factor: 12.531

Review 8.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

9.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

10.  Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.

Authors:  C Christofer Juhlin; Gerald Goh; James M Healy; Annabelle L Fonseca; Ute I Scholl; Adam Stenman; John W Kunstman; Taylor C Brown; John D Overton; Shrikant M Mane; Carol Nelson-Williams; Martin Bäckdahl; Anna-Carinna Suttorp; Matthias Haase; Murim Choi; Joseph Schlessinger; David L Rimm; Anders Höög; Manju L Prasad; Reju Korah; Catharina Larsson; Richard P Lifton; Tobias Carling
Journal:  J Clin Endocrinol Metab       Date:  2014-12-09       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.